// App-Quantinova.ai

PB1877 : ADJUSTING SURVIVAL DATA FOR TREATMENT CROSSOVER IN THE ELEVATE-TN TRIAL BY USING A HISTORICAL COHORT OF PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY IN FRONT-LINE CHRONIC LYMPHOCYTIC LEUKEMIA

Researchers

Presenter

  • Priyanka Gaitonde

Principal Investigators

  • Bengt Liljas

  • Bob Shaw

Medical Centers

  • AstraZeneca,Cambridge,Storbritannien

  • AstraZeneca, Gaithersberg, MD, United States,

  • AstraZeneca,Cambridge,Verenigd Koninkrijk

  • AstraZeneca,Cambridge,Royaume-uni

  • AstraZeneca,Gaithersburg, MD,Verenigde Staten

  • AstraZeneca,Gaithersburg,Estados Unidos

  • AstraZeneca,Gaithersburg,Stati Uniti

  • AstraZeneca, Gaithersburg, MD

  • AstraZeneca,Cambridge,Reino Unido

  • Astra Zeneca, Cambridge, United Kingdom

  • AstraZeneca,Gaithersburg, MD,Verenigde Staten

  • AstraZeneca,Cambridge,Reino Unido

  • AstraZeneca,Gaithersburg,États-unis

  • AstraZeneca,Cambridge,Vereinigtes Königreich

  • AstraZeneca,Cambridge,Соединённое Королевство

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Cross Over

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved